We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Destiny Pharma Plc | LSE:DEST | London | Ordinary Share | GB00BDHSP575 | ORD GBP0.01 |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 16.75 | 16.00 | 18.00 | 0.00 | 07:30:03 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 0 | -6.5M | -0.0683 | -2.45 | 15.96M |
TIDMDEST
RNS Number : 2340F
Destiny Pharma PLC
25 October 2018
THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE EU MARKET ABUSE REGULATION (596/2014). UPON THE PUBLICATION OF THE ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN.
Destiny Pharma plc
("Destiny Pharma" or the "Company")
Grant of Options
Brighton, United Kingdom - 25 October 2018 - Destiny Pharma (AIM: DEST), a clinical stage biotechnology company focused on the development of novel anti-microbial drugs, which address the global problem of anti-microbial resistance (AMR), announces that it has granted options ("Options") over 300,000 new ordinary shares of 1 pence each in the Company ("Ordinary Shares") (representing 0.69 per cent. of the Company's issued share capital) to Shaun Claydon, the Company's new Chief Financial Officer who joined the board after close of business yesterday. Mr. Claydon has no other options over, or holdings in, the Company's shares.
The Options represent awards under the Destiny Pharma Employee Long Term Incentive Plan 2018 approved by the Company on 25 January 2018 for EMI and non-tax advantaged options. 150,000 of the Options have been granted at a price of 76.5 pence per Ordinary Share, being the closing mid-market price of an Ordinary Share on 24 October 2018, which will vest on the third anniversary of the date of grant and are exercisable for ten years thereafter. The remainder of the Options have been granted at a price of 1 pence each, of which, 50,000 will vest on 31 January 2019, 100,000 will vest on 31 January 2020 and all will be exercisable for ten years thereafter.
For further information, please contact:
Destiny Pharma plc
Neil Clark, CEO
pressoffice@destinypharma.com
+44 (0)1273 704 440
FTI Consulting
Simon Conway / Victoria Foster Mitchell
destinypharma@fticonsulting.com
+44 (0) 20 3727 1000
Cantor Fitzgerald Europe (Nominated Adviser and Joint Broker)
Philip Davies / Will Goode, Corporate Finance
Andrew Keith, Healthcare Equity Sales
+44 (0)20 7894 7000
finnCap Ltd (Joint Broker)
Geoff Nash / Kate Bannatyne, Corporate Finance
Alice Lane, Corporate Broking
+44 (0)20 7220 0500
About Destiny Pharma
Destiny Pharma is an established, clinical stage, innovative biotechnology company focused on the development of novel medicines that represent a new approach to the treatment of infectious disease. These potential new medicines are being developed to address the need for new drugs for the prevention and treatment of life-threatening infections caused by antibiotic-resistant bacteria, often referred to as "superbugs". Tackling anti-microbial resistance has become a global imperative recognised by the World Health Organisation (WHO) and the United Nations, as well as the G7 and the G20 countries. For further information, please visit https://www.destinypharma.com
The notification set out below is provided in accordance with the requirements of the EU Market Abuse Regulation.
1 Details of the relevant person / person closely associated a) Name Shaun Claydon ----------------------------- -------------------------------- 2 Reason for the notification --------------------------------------------------------------- a) Position/status Chief Financial Officer ----------------------------- -------------------------------- b) Initial notification/ Initial notification Amendment ----------------------------- -------------------------------- 3 Details of the issuer --------------------------------------------------------------- a) Name Destiny Pharma plc ----------------------------- -------------------------------- b) LEI 213800O9WH9Z38EHAC95 ----------------------------- -------------------------------- 4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii each type of transaction; (iii each date; and (iv) each place where transactions have been conducted --------------------------------------------------------------- a) Description of the Options over Ordinary Shares financial instrument, type of instrument Identification code GB00BDHSP575 ----------------------------- -------------------------------- b) Nature of the transaction Grant of options ----------------------------- -------------------------------- c) Price(s) and volume(s) Price(s) Volume(s) 76.5 pence 150,000 ---------- 1 pence 50,000 ---------- 1 pence 150,000 ---------- ----------------------------- -------------------------------- d) Aggregated information - Aggregated volume As above - Price As above ----------------------------- -------------------------------- e) Date of the transaction 25 October 2018 ----------------------------- -------------------------------- f) Place of the transaction AIM ----------------------------- --------------------------------
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
END
DSHLLFIEIFLEFIT
(END) Dow Jones Newswires
October 25, 2018 11:05 ET (15:05 GMT)
1 Year Destiny Pharma Chart |
1 Month Destiny Pharma Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions